AR070581A1 - Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave - Google Patents
Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo graveInfo
- Publication number
- AR070581A1 AR070581A1 ARP090100409A ARP090100409A AR070581A1 AR 070581 A1 AR070581 A1 AR 070581A1 AR P090100409 A ARP090100409 A AR P090100409A AR P090100409 A ARP090100409 A AR P090100409A AR 070581 A1 AR070581 A1 AR 070581A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- radical
- formula
- alkyl
- bis
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 6
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title abstract 4
- 201000004792 malaria Diseases 0.000 title abstract 4
- 229960004191 artemisinin Drugs 0.000 title abstract 3
- 239000002243 precursor Substances 0.000 title abstract 3
- -1 alkyl radical Chemical class 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229930101531 artemisinin Natural products 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- PRTIIRUFABLAGM-UHFFFAOYSA-N 2-(4-methyl-1,3-thiazol-3-ium-5-yl)ethanol;dibromide Chemical compound [Br-].[Br-].CC=1[NH+]=CSC=1CCO.CC=1[NH+]=CSC=1CCO PRTIIRUFABLAGM-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229960004991 artesunate Drugs 0.000 abstract 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical group C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 abstract 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion farmacéutica que comprende al menos una sal de bis-tiazolio, compuesto de formula (1) o uno de sus precursores, y artemisinina o uno de sus derivados. La utilizacion de dicha asociacion para la preparacion de un medicamento destinado al tratamiento o a la prevencion del paludismo grave. Un kit para el tratamiento o la prevencion del paludismo grave. Reivindicacion 1: Asociacion, que comprende como principios activos una sal de bis-tiazolio, compuesto de formula (1) en la que Rb representa un grupo R1 que representa un átomo de hidrogeno, un radical alquilo C1-5, eventualmente sustituido con un radical arilo (principalmente un radical fenilo), un hidroxi, un alcoxi, en el que el radical alquilo comprende de 1 a 5 átomos de carbono, o ariloxi (principalmente fenoxi), o bien un grupo T, representando T el grupo de formula (2) en la que R2 representa un átomo de hidrogeno, un radical alquilo C1-5 o un grupo -CH2-COO-alquilo C1-5; R3 representa un átomo de hidrogeno, un radical alquilo o alquenilo C1-5, si es necesario sustituido con -OH, un grupo fosfato, un radical alcoxi, en el que el radical alquilo es de C1-3, o ariloxi; o un grupo alquilo o (aril)carboniloxi; o incluso R2 y R3 forman juntos un ciclo de 5 o 6 átomos de carbono; R2 y R3 pueden estar unidos para formar un ciclo o un heterociclo de 5 a 7 eslabones que comprende eventualmente uno o varios heteroátomos de O y/o S; Z representa un radical alquilo C6-21, principalmente de C12 o C13 a C21, si es necesario con la insercion de uno o varios enlaces multiples, y/o uno o varios heteroátomos de O y/o S, y/o uno o varios ciclos aromáticos, y las sales farmacéuticamente aceptables de estos compuestos, con la condicion de que Z no representa un radical alquilo C6-8, cuando Rc, Rd, R2 y R3 representan un radical metilo, o cuando Rc y Rd por una parte, y R2 y R3 por otra parte, forman juntos ciclos aromáticos de 6 átomos de carbono; Rd representa R2 tal como se ha definido anteriormente o P, representando P el grupo de formula (3); Rc representa R3 tal como se ha definido anteriormente o U, representando U el grupo de formula (4) entendiéndose que Rb = T, si Rc = R3 y Rd = R2; Rd = P, si Rc = R3 y Rb = R1; y Rc = U, si Rb = R1 y Rd = R2; en forma de una base libre, sal, hidrato o solvato, o uno de sus precursores, y artemisinina o uno de sus derivados, para el tratamiento y/o la prevencion del paludismo grave. Reivindicacion 6: Composicion farmacéutica segun la reivindicacion 5, caracterizada porque la sal de bis-tiazolio, compuesto de formula (1) es dibromuro de 1,12-dodecametilenobis[4-metil-5-(2-hidroxietil)tiazolio]. Reivindicacion 7: Composicion farmacéutica segun la reivindicacion 5 o la reivindicacion 6, caracterizada porque el derivado de artemisinina es artesunato. Reivindicacion 8: Composicion farmacéutica segun una cualquiera de las reivindicaciones 5 a 7; caracterizada porque está adaptada para la administracion oral, rectal o inyectable, y preferiblemente adaptada para inyeccion intravenosa, particularmente en forma de perfusion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800618A FR2926993B1 (fr) | 2008-02-06 | 2008-02-06 | Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artemisinine ou l'un de ses derives pour le traitement du paludisme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070581A1 true AR070581A1 (es) | 2010-04-21 |
Family
ID=39705083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100409A AR070581A1 (es) | 2008-02-06 | 2009-02-06 | Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US8304440B2 (es) |
| EP (1) | EP2252286B1 (es) |
| JP (1) | JP5469095B2 (es) |
| KR (1) | KR20100137442A (es) |
| CN (1) | CN101980706B (es) |
| AP (1) | AP2613A (es) |
| AR (1) | AR070581A1 (es) |
| AT (1) | ATE521347T1 (es) |
| AU (1) | AU2009227092B2 (es) |
| BR (1) | BRPI0907484A2 (es) |
| CA (1) | CA2714184A1 (es) |
| CL (1) | CL2009000264A1 (es) |
| CO (1) | CO6300843A2 (es) |
| CR (1) | CR11613A (es) |
| CY (1) | CY1112113T1 (es) |
| DK (1) | DK2252286T3 (es) |
| EA (1) | EA022711B1 (es) |
| EC (1) | ECSP10010381A (es) |
| ES (1) | ES2372148T3 (es) |
| FR (1) | FR2926993B1 (es) |
| HR (1) | HRP20110858T8 (es) |
| IL (1) | IL207442A0 (es) |
| JO (1) | JO2820B1 (es) |
| MA (1) | MA32128B1 (es) |
| MX (1) | MX2010008653A (es) |
| MY (1) | MY150776A (es) |
| NI (1) | NI201000135A (es) |
| NZ (1) | NZ587232A (es) |
| PA (1) | PA8815101A1 (es) |
| PE (1) | PE20091410A1 (es) |
| PL (1) | PL2252286T3 (es) |
| PT (1) | PT2252286E (es) |
| RS (1) | RS52046B (es) |
| SI (1) | SI2252286T1 (es) |
| TW (1) | TWI402071B (es) |
| UA (1) | UA99510C2 (es) |
| UY (1) | UY31640A1 (es) |
| WO (1) | WO2009115666A2 (es) |
| ZA (1) | ZA201005611B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2951945B1 (fr) * | 2009-11-05 | 2013-08-09 | Sanofi Aventis | Composition pharmaceutique |
| AU2014346668C1 (en) | 2013-11-08 | 2018-04-26 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
| US10714230B2 (en) * | 2017-12-06 | 2020-07-14 | C3Nano Inc. | Thin and uniform silver nanowires, method of synthesis and transparent conductive films formed from the nanowires |
| CN110604733A (zh) * | 2019-09-19 | 2019-12-24 | 同济大学 | 青蒿素类药物与其它药物联用在制备抗疟疾药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1058717A (zh) * | 1990-08-08 | 1992-02-19 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗疟新药—复方蒿甲醚及其制备方法 |
| FR2796642B1 (fr) * | 1999-07-21 | 2001-10-19 | Centre Nat Rech Scient | Precurseurs de sels de bis-ammonium quaternaire et leurs applications comme prodrogues ayant une activite anti-parasitaire |
| JP2003050535A (ja) * | 2001-08-07 | 2003-02-21 | T-Zone Corp | ネットワーク教育システム、ネットワーク教育方法、および、プログラム |
| FR2884715B1 (fr) * | 2005-04-20 | 2007-06-15 | Sanofi Aventis Sa | Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme |
-
2008
- 2008-02-06 FR FR0800618A patent/FR2926993B1/fr not_active Expired - Fee Related
-
2009
- 2009-02-01 JO JO200952A patent/JO2820B1/en active
- 2009-02-04 PE PE2009000161A patent/PE20091410A1/es not_active Application Discontinuation
- 2009-02-05 BR BRPI0907484A patent/BRPI0907484A2/pt not_active IP Right Cessation
- 2009-02-05 CA CA2714184A patent/CA2714184A1/fr not_active Abandoned
- 2009-02-05 MY MYPI20103671 patent/MY150776A/en unknown
- 2009-02-05 UA UAA201010670A patent/UA99510C2/ru unknown
- 2009-02-05 CN CN2009801109704A patent/CN101980706B/zh not_active Expired - Fee Related
- 2009-02-05 DK DK09721879.6T patent/DK2252286T3/da active
- 2009-02-05 SI SI200930113T patent/SI2252286T1/sl unknown
- 2009-02-05 PT PT09721879T patent/PT2252286E/pt unknown
- 2009-02-05 ES ES09721879T patent/ES2372148T3/es active Active
- 2009-02-05 HR HR20110858T patent/HRP20110858T8/xx unknown
- 2009-02-05 EP EP09721879A patent/EP2252286B1/fr active Active
- 2009-02-05 EA EA201070923A patent/EA022711B1/ru not_active IP Right Cessation
- 2009-02-05 PL PL09721879T patent/PL2252286T3/pl unknown
- 2009-02-05 AU AU2009227092A patent/AU2009227092B2/en not_active Ceased
- 2009-02-05 JP JP2010545524A patent/JP5469095B2/ja not_active Expired - Fee Related
- 2009-02-05 NZ NZ587232A patent/NZ587232A/en not_active IP Right Cessation
- 2009-02-05 AT AT09721879T patent/ATE521347T1/de active
- 2009-02-05 MX MX2010008653A patent/MX2010008653A/es active IP Right Grant
- 2009-02-05 AP AP2010005353A patent/AP2613A/xx active
- 2009-02-05 PA PA20098815101A patent/PA8815101A1/es unknown
- 2009-02-05 CL CL2009000264A patent/CL2009000264A1/es unknown
- 2009-02-05 KR KR1020107019691A patent/KR20100137442A/ko not_active Abandoned
- 2009-02-05 WO PCT/FR2009/000129 patent/WO2009115666A2/fr not_active Ceased
- 2009-02-05 RS RS20110508A patent/RS52046B/sr unknown
- 2009-02-06 UY UY031640A patent/UY31640A1/es not_active Application Discontinuation
- 2009-02-06 TW TW098103960A patent/TWI402071B/zh not_active IP Right Cessation
- 2009-02-06 AR ARP090100409A patent/AR070581A1/es unknown
-
2010
- 2010-07-29 CR CR11613A patent/CR11613A/es not_active Application Discontinuation
- 2010-08-03 NI NI201000135A patent/NI201000135A/es unknown
- 2010-08-05 EC EC2010010381A patent/ECSP10010381A/es unknown
- 2010-08-05 IL IL207442A patent/IL207442A0/en not_active IP Right Cessation
- 2010-08-05 ZA ZA2010/05611A patent/ZA201005611B/en unknown
- 2010-08-06 US US12/851,747 patent/US8304440B2/en not_active Expired - Fee Related
- 2010-08-06 CO CO10096216A patent/CO6300843A2/es not_active Application Discontinuation
- 2010-09-01 MA MA33132A patent/MA32128B1/fr unknown
-
2011
- 2011-11-24 CY CY20111101156T patent/CY1112113T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| AR061666A1 (es) | Derivados de bencimidazol, metodo de produccion de los mismos y preparaciones farmaceuticas que los contienen | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| MX2010005824A (es) | Derivados de aminotiazol. | |
| AR055060A1 (es) | Derivados de n-(piridin-2-il)-sulfonamida | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ECSP11010973A (es) | Nuevas combinaciones de compuestos heterocíclicos nitrogenados antibacterianos con otros compuestos antibacterianos y su utilización como medicamentos | |
| AR090041A1 (es) | Aril dihidropiridinona y piperidinona como inhibidores de mgat2 | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
| RU2010125903A (ru) | Новое производное катехина, фармацевтическая композиция, содержащая производное катехина, применение производного катехина и применение фармацевтической композиции | |
| AR070581A1 (es) | Asociacion entre una sal de bis-tiazolio o uno de sus precursores y artemisinina o uno de sus derivados para el tratamiento del paludismo grave | |
| SV2009003391A (es) | Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos ref. 26480sv novx54 mg | |
| PT2026799E (pt) | Derivados de imidazolidina, utilizações para estes, preparação destes e composições compreendendo-os | |
| WO2008012782A3 (en) | Labelled analogues of halobenzamides as radiopharmaceuticals | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| GEP20125548B (en) | New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them | |
| ES2530815T3 (es) | Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| JP2007514639A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |